Evercore ISI Group Downgrades Ventyx Biosciences to In-Line, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Josh Schimmer has downgraded Ventyx Biosciences (VTYX) from Outperform to In-Line and significantly reduced the price target from $43 to $5.
November 10, 2023 | 8:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ventyx Biosciences has been downgraded by Evercore ISI Group from Outperform to In-Line, with a drastic cut in the price target from $43 to $5.
The downgrade from 'Outperform' to 'In-Line' suggests that the analyst no longer sees the stock outperforming the market or its sector. The significant reduction in the price target from $43 to $5 indicates a substantial change in the expected performance of the company's stock, which could lead to a negative short-term impact on its share price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100